A major limiting factor in discovering new insights into the pathogenesis of sarcoidosis is the lack of a viable disease model. FSR has identified research within a Sarcoidosis Disease Model as one of the critical investments of our focus, and has designated significant funding toward this initiative. In a two-phase plan, FSR is funding early stage research in this area. The FSR Model Grant opportunity will serve to ignite additional research and will help bridge funding for much-needed larger investments into the disease model space from industry, academia, and venture philanthropy.
This initial grant’s Request For Applications (RFA) was opened in Fall 2016 with funding selections made in Spring 2017. A grant amount, totaling $750,000 for five awardees, will allow the following partners to complete two-year projects towards the development, characterization, or improvement of a sarcoidosis disease model:
- Medical University of Vienna – Thomas Weichhart, PhD
Characterization and Improvement of a Novel Mouse Model that Spontaneously Develops Progressive Sarcoidosis by Chronic Activation of mTORC1
- Ohio State University – Elliott Crouser, MD, Larry Schlesinger, MD, Wolfgang Sadee, Dr.rer.nat, Peter White, PhDA Novel In Vitro Human Granuloma Model of Sarcoidosis
- University of Freiburg – Peggy Engelhard, PhD, Gernot Zissel,PhD, Joachim Müller-Quernheim, MD, Marina A. Freudenberg, MDModels for the investigations of the involvement of type I interferon (IFN-aB) in the pathogenesis of sarcoidosis
- University of Hull, York Medical School – Simon Hart, MBChB, PhDDevelopment and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease
- Yale School of Medicine – Erica Herzog, MD, PhDDevelopment of an ex vivo mimetic of the Sarcoidosis lung microenvironment
Following early research made possible by this grant, FSR will then strategize to fund another $1.5 million-plus for a continuation phase of the above grant with the goal of the resulting research to stimulate interest from long-term investors.